Ami Fadia
Stock Analyst at Needham
(4.47)
# 296
Out of 5,156 analysts
353
Total ratings
48.73%
Success rate
24.48%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Reiterates: Buy | $14 | $3.89 | +259.90% | 2 | Mar 9, 2026 | |
| IMRX Immuneering | Reiterates: Buy | $11 | $5.62 | +95.73% | 21 | Mar 9, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Hold | n/a | $21.33 | - | 24 | Mar 6, 2026 | |
| GHRS GH Research | Maintains: Buy | $31 → $32 | $15.98 | +100.25% | 4 | Mar 6, 2026 | |
| RVMD Revolution Medicines | Maintains: Buy | $150 → $145 | $99.79 | +45.31% | 28 | Feb 26, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $46 → $44 | $28.57 | +54.01% | 40 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $225 | $164.49 | +36.79% | 19 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $187 → $185 | $129.93 | +42.38% | 17 | Feb 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $460 → $510 | $309.01 | +65.04% | 17 | Feb 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $210 → $235 | $185.40 | +26.75% | 35 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $37.01 | - | 24 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $29 | $22.58 | +28.43% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $28.45 | +54.66% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $3.22 | +148.45% | 10 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $188.24 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.09 | +34.15% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $5.38 | +439.03% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $14.58 | +2,094.79% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $22.24 | +237.23% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.18 | +12,483.89% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $10.29 | +512.24% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $31.50 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.00 | +2,107.73% | 4 | Jan 3, 2018 |
AtaiBeckley
Mar 9, 2026
Reiterates: Buy
Price Target: $14
Current: $3.89
Upside: +259.90%
Immuneering
Mar 9, 2026
Reiterates: Buy
Price Target: $11
Current: $5.62
Upside: +95.73%
Day One Biopharmaceuticals
Mar 6, 2026
Downgrades: Hold
Price Target: n/a
Current: $21.33
Upside: -
GH Research
Mar 6, 2026
Maintains: Buy
Price Target: $31 → $32
Current: $15.98
Upside: +100.25%
Revolution Medicines
Feb 26, 2026
Maintains: Buy
Price Target: $150 → $145
Current: $99.79
Upside: +45.31%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $28.57
Upside: +54.01%
Axsome Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $225
Current: $164.49
Upside: +36.79%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Buy
Price Target: $187 → $185
Current: $129.93
Upside: +42.38%
Praxis Precision Medicines
Feb 4, 2026
Maintains: Buy
Price Target: $460 → $510
Current: $309.01
Upside: +65.04%
Jazz Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $185.40
Upside: +26.75%
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $37.01
Upside: -
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $22.58
Upside: +28.43%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $28.45
Upside: +54.66%
Oct 28, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $3.22
Upside: +148.45%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $188.24
Upside: -
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $26.09
Upside: +34.15%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $5.38
Upside: +439.03%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $14.58
Upside: +2,094.79%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $22.24
Upside: +237.23%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.18
Upside: +12,483.89%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $10.29
Upside: +512.24%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $31.50
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.00
Upside: +2,107.73%